TC |
Stat |
Stk |
Ins |
Fil |
+d |
+w |
+m |
+q |
+h |
+y |
avg |
|---|
Filing Date |
T Date |
Ticker |
Issuer | Inc | Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
#f |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
8/22/25 16:30 | 8/20/25 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Chase William J | MA | D | 1 | P | 1,003 | 10.03 | 0 | 100 | 288 | 135 | D | |||||||||||||||
8/6/25 09:00 | 8/5/25 | VNRX | Volitionrx Ltd | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Innes Guy Archibald | NV | D | 2 | P | 61 | 0.6193 | 0 | 98 | 3 | 3,341 | D | |||||||||||||||
8/6/25 09:00 | 8/5/25 | VNRX | Volitionrx Ltd | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Reynolds Cameron John | NV | DO | P,CEO | 2 | P | 57 | 0.6331 | 0 | 91 | 3 | 3,652 | D | ||||||||||||||
6/12/25 17:09 | 6/12/25 | ICCC | Immucell Corp /De/ | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Gathagan Bryan K. | ME | D | 1 | P | 6 | 6.32 | 0 | 1 | 1 | D |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |